Table 3 Prognosis across composite risk score subpopulations.

From: Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

Subpopulation

Size

Median CPRS

Minimum CPRS

Maximum CPRS

HR

95% CI

1

302

1.23

0.00

1.49

0.96

0.38–2.42

2

300

1.34

0.70

1.59

0.90

0.41–1.94

3

301

1.42

1.12

1.70

0.89

0.44–1.82

4

302

1.51

1.26

1.82

1.08

0.56–2.07

5

304

1.62

1.36

1.92

1.06

0.60–1.89

6

300

1.76

1.44

2.03

0.94

0.54–1.62

7

306

1.87

1.52

2.08

0.86

0.50–1.46

8

300

1.96

1.65

2.15

0.78

0.45–1.34

9

301

2.04

1.78

2.22

0.85

0.52–1.41

10

302

2.08

1.88

2.34

0.71

0.43–1.16

11

300

2.15

1.97

2.45

0.55

0.33–0.91

12

301

2.23

2.06

2.61

0.47

0.28–0.78

13

300

2.37

2.09

2.75

0.48

0.30–0.77

14

305

2.47

2.16

2.82

0.66

0.43–1.03

15

303

2.65

2.27

2.96

0.79

0.52–1.20

16

300

2.78

2.38

3.29

0.81

0.54–1.21

17

273

2.82

2.49

3.91

0.91

0.61–1.38

  1. CPRS composite risk score, HR hazard ratio.
  2. Subgroups were defined according to the median composite risk score, interaction P value based on hazard ratio estimates: 0.3084.
Back to article page